Metraipolis › archive › dc_01dd8b2df62d
Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer — Europe PMC PMID:41496420
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41496420
- DOI
- 10.1016/j.breast.2026.104693
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T02:25:38.970Z
- SHA-256 of the archived text
cd5d5ca557fb51587d1ff36a7acbf333714b6c9223b63a96520382d9bb3a5c6c- Stable URL of this page
https://metraipolis.com/documento/dc_01dd8b2df62d
How to cite
Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer — Europe PMC PMID:41496420 — Europe PMC (en), https://europepmc.org/article/MED/41496420 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_01dd8b2df62d (Metraipolis archive dc_01dd8b2df62d, sha256 cd5d5ca557fb51587d1ff36a7acbf333714b6c9223b63a96520382d9bb3a5c6c)
BibTeX
@misc{dc01dd8b2df62d,
title = {Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer — Europe PMC PMID:41496420},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41496420},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_01dd8b2df62d; sha256 cd5d5ca557fb51587d1ff36a7acbf333714b6c9223b63a96520382d9bb3a5c6c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41496420. Agents can read the archived copy with the MCP tool read_document.